Comparative Pharmacology
Head-to-head clinical analysis: INVEGA versus OLANZAPINE AND FLUOXETINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVEGA versus OLANZAPINE AND FLUOXETINE HYDROCHLORIDE.
INVEGA vs OLANZAPINE AND FLUOXETINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paliperidone is the major active metabolite of risperidone. It is a benzisoxazole derivative antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also acts as an antagonist at α1 and α2 adrenergic receptors and H1 histaminergic receptors. It has no affinity for muscarinic receptors.
Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI). The combination modulates serotonergic and dopaminergic pathways to treat depressive episodes in bipolar I disorder.
Oral: 6 mg once daily; may increase to 9 mg/day if needed. IM (extended-release): 234 mg on day 1, 156 mg on day 8, then 117 mg monthly; adjust within range 39-234 mg per month.
Olanzapine 6 mg / fluoxetine 25 mg orally once daily in the evening, with dose adjustments based on response and tolerability.
None Documented
None Documented
Terminal elimination half-life is approximately 23-29 hours for oral administration (paliperidone extended-release). Once-daily dosing achieves steady-state within 4-5 days.
Olanzapine: 30 h (young adults); 50 h (elderly). Fluoxetine: 4-6 days (single dose), 4-6 days (norfluoxetine); longer with chronic dosing (up to 6-8 weeks to steady state). Clinical context: drug accumulates over weeks.
Primarily renal: 59-80% of dose excreted unchanged in urine (as parent drug and metabolites). Fecal: ~20-30%. Biliary elimination is minimal.
Olanzapine: ~57% renal (metabolites), ~30% fecal. Fluoxetine: ~80% renal (metabolites, mainly norfluoxetine), ~15% fecal.
Category C
Category A/B
Atypical Antipsychotic
Atypical Antipsychotic